CLAIMS

1. Use of a dosage form comprising 0.125 mg to 0.145 mg of levonorgestrel (LNG) in the manufacture of a medicament for providing contraception to a human subject desiring contraception, wherein the medicament is to be orally administered to the subject once a day for a treatment period of at least twenty-eight days wherein the LNG is the only pharmaceutical active agent, additive or adjuvant to be administered for contraceptive purposes during the treatment period; and wherein no estrogen compound is to be administered to the subject during the treatment period.

2. The use of claim 1 wherein the dosage form comprises 0.125 mg of LNG, 0.130 mg of LNG, 0.135 mg of LNG, 0.140 mg of LNG or 0.145 mg of LNG and at least one pharmaceutically acceptable excipient.

3. The use of claim 1 wherein no folate is to be administered to the subject during the treatment period.

4. The use of claim 1 wherein there is no dose titration of the LNG during the treatment period.

5. The use of claim 1 wherein the medicament comprising of the LNG dosage form is to be administered to the subject once a day for a treatment period of at least 55 days or longer without a break in the administration of the said LNG dosage form.

6. The use of claim 1 wherein the medicament comprising of the LNG dosage form is to be administered to the subject once a day for a treatment period of at least 180 days or longer without a break in the administration of the said LNG dosage form.

7. The use of claim 1 wherein the dosage form is a tablet comprising the LNG and at least one pharmaceutically acceptable excipient.

8. Use of a tablet consisting of 0.130 mg to 0.140 mg of levonorgestrel (LNG) and one or more pharmaceutically acceptable excipients in the manufacture of a medicament for providing contraception to a human subject desiring contraception, wherein the medicament is to be orally administered to the subject for a treatment period of at least twenty-eight days wherein the LNG is the only pharmaceutical active agent, additive or adjuvant to be administered for contraceptive purposes during the treatment period; and wherein no estrogen compound is to be administered to the subject during the treatment period.

9. The use of claim 10 wherein the tablet comprises 0.135 mg of LNG and at least one pharmaceutically acceptable excipient selected from the lubricants, fillers, binders, disintegrants, glidants, solubilizing agents, flavoring agents, pH adjusting agents, antioxidants, chelating agents, or mixtures of the foregoing.

10. The use of claim 8 wherein no folate is to be administered to the subject during the treatment period.

11. The use of claim 8 wherein there is no dose titration of the LNG during the treatment period.

12. The use of claim 8 wherein the medicament comprising of the LNG tablet is to be administered to the subject once a day for a treatment period of at least 60 days or longer without a break in the administration of the said LNG tablet.

13. The use of claim 8 wherein the medicament comprising of the LNG tablet is to be administered to the subject once a day for a treatment period of at least 180 days or longer without a break in the administration of the said LNG tablet.